ABT · NYSE · Health Care Equipment
Health Care Equipment company based in North Chicago, Illinois.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
4 sales
$46.9M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$44.3B
+5.7% vs the year before
Net income, fiscal 2025
$6.52B
As reported in the annual filing
Shares outstanding
1.74B
As of Mar 31, 2026
In fiscal 2025 the company spent $893M buying back its own shares and $4.12B on dividends. Cash actually paid, from its cash-flow statement.
Traded 48 days after results
25K → 25K shares held
Abbott Laboratories's VICE PRESIDENT AND CONTROLLER sold $3K of Abbott Laboratories shares. Nobody planned it ahead of time.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Traded 40 days after results
705K → 487K shares held−31% of their stake
The boss of Abbott Laboratories sold $25.3M of Abbott Laboratories shares. Nobody planned it ahead of time.
Traded 40 days after results
487K → 306K shares held−37% of their stake
The boss of Abbott Laboratories sold $20.9M of Abbott Laboratories shares. Nobody planned it ahead of time.
Congress tradeSits on House Energy and Commerce7 different filers disclosed ABT within 90 days. Disclosed 35 days after the transaction; reported as an official range, not an exact amount.
25 certified in FY2026 Q3, vs 33 a year earlier. 25 positions in total, median offered wage $110K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Foreign-Trade Zone (FTZ) 39, Notification of Proposed Production Activity; Abbott Laboratories; (Diagnostic Medical Devices); Irving, Texas
Notice · Foreign-Trade Zones Board
Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots
Proposed rule · Centers for Medicare & Medicaid Services
Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Syntest D.S. and Syntest H.S. Tablets; Withdrawal of Hearing Requests; Final Resolution of Drug Efficacy Study Implementation 7661
Notice · Food and Drug Administration
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
15 approvals or clearances and 8 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
